Atracurium

• Description:

  Tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation[1][2][3][4][5].

• Product Name Alternative:

  BW-33A (free acid)

• UNSPSC:

  12352005

• Target:

  NAChR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/atracurium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OCCCCCOC(CC[N+]1(C)C(CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N+]4(C)C(CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4

• Molecular Formula:

  C53H72N2O12+2

• Molecular Weight:

  929.14

• References & Citations:

  [1]Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A) : a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61 (9) :723-9.|[2]Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151 (5) :1537-42.|[3]Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18 (9) :599-604.|[4]Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7 (1) :459-72.|[5]Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95 (1) :9-14.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [64228-79-1]